NEW YORK, October 6, 2017 /PRNewswire/ --
If you want a Stock Review on BAX, ATRS, IART, or BDX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Research coverage has been initiated by DailyStockTracker.com on Baxter International Inc. (NYSE: BAX), Antares Pharma Inc. (NASDAQ: ATRS), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and Becton, Dickinson and Co. (NYSE: BDX). These companies are part of the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:
On Thursday, shares in Deerfield, Illinois headquartered Baxter International Inc. saw a slight drop of 0.30%, ending the day at $62.71. The stock recorded a trading volume of 1.79 million shares. The Company's shares have advanced 0.29% in the last one month, 3.28% over the previous three months, and 41.43% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.30% and 12.93%, respectively. Moreover, shares of Baxter, which provides a portfolio of renal and hospital products, have a Relative Strength Index (RSI) of 50.81.
On September 27th, 2017, Baxter announced the launch of DeviceVue, a comprehensive, asset-tracking solution available exclusively to hospitals using the Sigma Spectrum Infusion System. Designed to help enhance clinical and hospital efficiency, DeviceVue helps enable clinicians and biomedical engineers to quickly find unused pumps by viewing pump location and status data from their PC, iPad®, or iPhone®. BAX complete research report is just a click away at:
Shares in Ewing, New Jersey headquartered Antares Pharma Inc. ended the day 2.33% lower at $3.77. A total volume of 2.95 million shares was traded, which was above their three months average volume of 1.25 million shares. In the last month and the previous three months, the stock has gained 24.83% and 18.18%, respectively. Additionally, the Company's shares have surged 61.80% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 22.13% and 36.17%, respectively. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 77.52. The complimentary report on ATRS can be downloaded at:
Integra LifeSciences Holdings
At the close of trading on Thursday, shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. finished 0.23% lower at $51.65 with a total trading volume of 314,165 shares. The stock has advanced 0.33% in the last one month and 20.41% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 2.70% and 9.55%, respectively. Additionally, shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 57.24.
On October 03rd, 2017, Integra LifeSciences announced that it has launched SurgiMend® PRS Meshed Collagen Matrix, its latest offering in tissue-building solutions for plastic and reconstructive surgery. SurgiMend PRS Meshed Collagen Matrix is an expandable matrix that provides up to twice the initial coverage area once hydrated and fully expanded. It features a meshing pattern, which allows for vascular in-growth and increased conformability. Sign up for your complimentary research report on IART at:
Becton, Dickinson and Co.
Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co.'s shares recorded a trading volume of 1.24 million shares at the end of yesterday's session, which was above their three months average volume of 1.13 million shares. The stock closed the day 1.15% higher at $197.25. The Company's shares have advanced 19.15% on an YTD basis. The stock is trading above its 200-day moving average by 5.28%. Additionally, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 53.56.
On September 22nd, 2017, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock, with a target price of $225 per share.
On September 26th, 2017, Becton, Dickinson and Co. announced the launch of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test will help hospitals identify and contain infections caused by CPO, while potentially combating an increase in antimicrobial resistance. Get free access to your research report on BDX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.